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Abstract: MDM family proteins are crucial regulators of the oncosuppressor p53. Alterations of their gene status, mainly 
amplification events, have been frequently observed in human tumors.  
MDM4 is one of the two members of the MDM family. The human gene is located on chromosome 1 at q32-33 and codes 
for a protein of 490aa. In analogy to MDM2, besides the full-length mRNA several transcript variants of MDM4 have 
been identified. Almost all variants thus far described derive from a splicing process, both through canonical and aberrant 
splicing events. Some of these variants are expressed in normal tissues, others have been observed only in tumor samples. 
The presence of these variants may be considered a fine tuning of the function of the full-length protein, especially in 
normal cells. In tumor cells, some variants show oncogenic properties. 
This review summarizes all the different MDM4 splicing forms thus far described and their role in the regulation of the 
wild type protein function in normal and tumor cells. In addition, a description of the full-length protein structure with all 
known interacting proteins thus far identified and a comparison of the MDM4 variant structure with that of full-length 
protein are presented. Finally, a parallel between MDM4 and MDM2 variants is discussed. 
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FULL-LENGTH MDM4 
Protein Domains 
  The murine Mdm4 protein (transformed mouse 3T3 cell 
double minute 4), formerly named Mdmx, has been identi-
fied in 1996 as a p53 binding protein [1]. It shows significant 
homology with the Mdm2 protein (transformed mouse 3T3 
cell double minute 2), the best known negative regulator of 
p53 (Trp53, transformation related protein 53), particularly 
in the N-terminal p53-binding domain and in the C-terminus 
of the protein [1]. The human homolog MDM4, (Mdm4 p53 
binding protein homolog) has been localized on chromosome 
1q32 [2]. Northern blot analysis has revealed a 10-kb human 
MDM4 transcript expressed in almost all tissues although 
with different proportions [2]. The mRNA comprises 11 ex-
ons, with the first AUG codon in the second exon. Despite 
the presence of additional in-frame AUG codons at positions 
46, 53 and 61 (starting from the first AUG), there is no evi-
dence of alternative transcripts originating from these start 
sites [2]. The MDM4 cDNA codes for a protein of 490 amino 
acids (aa) (489 in the mouse), with the exon 11 coding for 
the C-terminal last 189 aa. The structure of the protein is 
depicted in Fig. (1).  
  It comprises a p53 (human TP53, tumor protein 53) bind-
ing domain (BD) between amino acids 24 and 108 according 
to the NMR study of the analogous MDM2 (Mdm2 p53 
binding protein homolog) region [3]. The residues of MDM2  
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involved in p53 binding [4] are totally conserved in MDM4 
(G58, D68, V75, C77 corresponding to MDM4 G57, D67, 
V74, C76) and mutation of the first of them abolishes p53 
binding to MDM4 [5] suggesting high similarity in the asso-
ciation of MDM2 and MDM4 to p53 [6]. However, the crys-
tal structure of the p53-binding domain of MDM4 in com-
plex with a peptide derived from the p53 N-terminus (aa 17-
37), has revealed differences between MDM4 and MDM2 
binding to p53 [7,8]. Particularly, the hydrophobic cleft on 
which the transactivation domain of p53 binds is smaller in 
MDM4 than in MDM2. Coarse graining simulations have 
confirmed that recognition of p53 is favored in MDM2 with  
respect to MDM4 [9]. Further, the N-terminal lid of MDM2 
(aa 16-24) that competes for p53 binding under some cir-
cumstances, is not conserved in MDM4 [3]. As a further 
confirmation of the divergence existing between the p53 
binding domains of MDM4 and MDM2, the drug-like small 
molecule Nutlin-3a disrupts the MDM4-p53 complex at a 
concentration much higher than that required to disrupt 
MDM2-p53 [8, 10-13]. 
  The other region with high similarity between MDM4 
and MDM2 is the C-terminus containing the RING finger 
motif (aa 437-477). Whereas this motif mediates ubiquitin 
ligase activity in MDM2, [14, 15] it doesn’t confer the same 
function to MDM4 in vivo [16]. Nevertheless, various   
groups have shown the ability of MDM4 to potentiate E3 
ubiquitin ligase activity of MDM2 and/or to restore function 
of inactive mutant MDM2 suggesting that MDM4 can con-
tribute to the MDM2 E3 function [17-21]. In addition, the 
RING finger mediates MDM4-MDM2 association [22-24] 
although the extreme C-terminus of both proteins is neces- 
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sary too for their interaction [20, 25]. The residues involved 
in MDM2-MDM4 interaction have been recognized in some 
hydrophobic residues (of the RING finger of MDM2) [21]. 
In addition, mutation of the amino acids disrupting the RING 
finger structure abolishes this association as well [22, 24].  
  Within the RING finger a potential nuclear localization 
signal has been mapped (aa 465-469) composed of a stretch 
of basic amino acids (RRLKK) [1]. This site has been sug-
gested to mediate nuclear translocation of MDM4 after DNA 
damage. Indeed, point mutation of a lysine in this stretch 
abolishes nuclear translocation of MDM4 and its binding to 
the cytoplasmic receptor importin  [26]. 
  Another recognizable region in MDM4 is the Zinc finger 
motif between aa 300 and 328. This is a C4 Zinc finger motif 
of the RanBP2-type Zinc finger family. Particularly, it can 
be assigned to the related polypeptide family termed Npl4 
Zinc finger (NZF), characterized by the presence of only two 
residues between the first two cysteines [27]. The RanBP2/ 
NZF fingers have been described as ubiquitin recognition 
motifs, but the lack in MDM4 of the T13F14/M25 residues 
would exclude this function [28] leaving unknown the func-
tion of this domain. 
  Close to the Zinc finger motif, it is present a tetrapeptide 
that represents a canonical caspase cleavage signal (aa 357-
361, DVPD) [29]. Indeed, this site is sensitive to caspase 
activity. The caspase cleavage of MDM4 at this site has been 
shown to affect protein stability [29].  
  The central region of MDM4 is rich in acidic residues 
and for this reason is indicated as acidic domain [16]. So far 
no specific activities have been attributed to this portion of 
the protein. 
  Finally, some residues of MDM4 have been recognized 
as specific targets of post translational modification:  
•  K254 and K379 have been identified as SUMO-1 targets. 
These modifications do not alter MDM4 stability and 
subcellular localization nor its inhibitory activity toward 
p53 transcriptional function, leaving unknown the role of 
these sumoylations [30]; 
•  S96 is phosphorylated by cyclin-dependent kinase 1 (CD- 
K1/Cdc2
p34). The mutation S96A redistributes MDM4 in 
the nucleus suggesting that the phosphorylation of this 
site may affect MDM4 subcellular localization [31]; 
•  S289 is phosphorylated by Casein Kinase 1 (CK1) 
This modification strengthens the association between 
MDM4 and p53 and the inhibition of p53 transcriptional 
function by MDM4 [32];  
•  S342 is phosphorylated by Checkpoint Kinases 1 and 2 
(Chk1/Chk2) [33, 34]. This modification, as that of the 
S367 site (see below), is present in U2OS cell line under 
normal growth conditions but is highly increased after IR 
[33]. The phosphorylation of this site mediates enhanced 
degradation of MDM4 [33-35]. Comparative in vitro as-
says indicate that Chk1 is more efficient than Chk2 in in-
ducing this phosphorylation although in vivo the knock-
out (KO) of Chk2 abolishes the DNA-damage induced 
Ser342
P [33]; 
•  S367 is phosphorylated by Chk1/Chk2/Akt [33, 34, 36, 
37]. As for S342, the phosphorylation at this MDM4 site 
is detectable also under normal growth conditions al-
though DNA damage strongly induces it [33, 34, 36, 38]. 
Phosphorylation at this site regulates MDM4 stability 
[33-35, 37, 38] and induces binding of different 14-3-3 
isoforms to MDM4 (See the following 14-3-3 paragraph); 
•  S403 is phosphorylated by ataxia telangiectasia mutated 
(ATM) [35]. It is induced by DNA damage and the 
S403A MDM4 mutant is more stable than the wild-type 
(wt) protein indicating also for this phosphorylation a 
role in MDM4 degradation [35]. 
MDM4 INTERACTIONS 
P53 Family Members 
  MDM4 has been identified by Jochemsen’s group as a 
p53 binding protein [1]. P53 is one of the main human onco-
suppressor genes and is involved in a plethora of cell func-
tions. The crucial role of MDM4 in the regulation of p53 has 
been assessed by the KO Mdm4 mice. Mdm4
-/- mice die in 
utero but their death is rescued by concomitant deletion of 
the Trp53 gene [39-41]. At the molecular levels, the different 
activities exerted by MDM4 and MDM2 toward p53 have 
led to the proposal of three different models of inhibition of 
p53 function, still debated in the scientific community [42]. 
  In addition to p53, the BD of MDM4 is probably respon-
sible for the association of MDM4 to the other p53 family 
member, p73 although this has not been experimentally 







Fig. (1). Scheme of MDM4 protein domains and of regions involved in protein-protein interaction. The interaction proteins validated by in 
vivo binding assays are shown. Bold characters represent validated serine phosphorylation sites. Italic characters represent lysine sumoyla-
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to p63 and p63 both the TA and DN variants, have been 
excluded by two groups suggesting the existence of differ-
ences among the p53 family members [44,45]. The activity 
of MDM4 toward p73 confirms its transcriptional inhibi-
tory function [44]. 
MDM2 
  The binding between MDM4 and MDM2 leads to the 
formation of a heterodimer, which possesses higher stability 
in comparison to the homodimer of each protein [18, 21, 23]. 
In MCF7, majority of MDM4 is in complex with MDM2 
suggesting that the heterodimer is the predominant form into 
the cell [24]. However, the function of the heterodimer has 
not been completely clarified. Indeed, whereas a growing 
body of evidence suggests a cooperation of MDM4 in the E3 
ligase activity of MDM2 [17-21, 24], a recent report has evi-
denced the lower stability of a temperature-sensitive mutant 
p53 (p53A135V) protein in mouse embryo fibroblasts de-
rived from Mdm4-/- mice [46] suggesting the existence of an 
antagonizing function of endogenous MDM4 toward the 
degradative activity of MDM2, at least under some condi-
tions. In addition, it has been reported an antagonizing func-
tion of MDM4 toward MDM2-degradative activity when the 
levels of overexpressed MDM4 exceed those of MDM2 [16].  
14-3-3 Proteins 
  The interaction of MDM4 with 14-3-3 family has 
emerged in recent years. Although a detailed comparison of 
the affinity of MDM4 to the seven 14-3-3 members has not 
been carried out, the 14-3-3 form seems the less efficient in 
this association [26, 36-38]. The MDM4 region involved in 
such interaction has been recognized in the peptide 363-369 
of MDM4. Particularly, the amino acid S367 is the phos- 
phorylable key residue responsible of this association [26, 
34, 36-38]. In addition, the region surrounding residue S342 
affects the binding between MDM4 and 14-3-3, at least un-
der normal growth conditions [34]. The outcome resulting 
from MDM4/14-3-3 association is really puzzling: the major 
and more detailed effect is the nuclear degradation of 
MDM4 [26, 34, 38], however stabilization [37] as well as 
increased cytoplasmic localization of MDM4 [36] have been 
reported too. Whether these different results rely on the 
S367-phosphorylation  accompanying modifications, or/and 
on the type of 14-3-3 isoform bound to MDM4, and/or on 
the DNA damage conditions, it remains to be ascertained. 
Other Proteins  
CK1 (Casein Kinase 1) 
  MDM4 associates to CK1 through a large region en-
compassing the acidic and the Zinc finger regions and this 
association has been proven necessary to the MDM4-
mediated inhibition of p53 [32]. 
CDK1/Cdc2
p34 (Cyclin-Dependent Kinase 1) 
  The association of murine MDM4 to the endogenous 
Cdc2 has been shown by means of the overexpression of 
MDM4. The region responsible for the association has not 
been mapped. It has been hypothesized that this association 
mediates phosphorylation of MDM4 on aa S96 that in turn 
affects MDM4 subcellular localization [31]. 
E2F1 
  The interaction of MDM4 with this factor has been as-
sessed by GST-pull down assay and yeast two hybrid screen 
[47]. These studies have indicated the MDM4 region next to 
the C-terminus of the BD important for this association [47]. 
Nevertheless, this association has not been confirmed by in 
vivo coimmunoprecipitation experiments [48]. A reduction 
of MDM4 protein levels has been reported following over-
expression of E2F1 [49] although the molecular mechanisms 
underlying this reduction remain to be clarified as well as the 
biological significance of it. Conversely, the ability of 
MDM4 to repress E2F1 transactivation has been reported 
[48]. Whether the E2F1-MDM4 association is responsible 
for any of these effects has not been tested. 
Hausp/USP7 (Ubiquitin Specific Peptidase 7) 
  A direct binding of the deubiquitinating enzyme Hausp 
with MDM4 has been described by Jochemsen’s group [50]. 
The behavior of MDM4 deletion mutants has indicated that 
the p53 binding domain of MDM4 is sufficient to coim-
munoprecipitate Hausp. However, a MDM4 mutant lacking 
this domain is still able to bind Hausp with efficiency similar 
to the wt-protein suggesting that another not well defined 
region of MDM4 may mediate Hausp binding. The binding 
of Hausp to MDM4 contributes to stabilize MDM4 protein 
levels, by counteracting its MDM2-mediated degradation. 
The current model suggests that in normal growing cells 
MDM4 levels are controlled by a balanced association with 
Hausp and MDM2. Under DNA damage, Hausp association 
to MDM4 is attenuated in an ATM dependent manner lead-
ing to a decrease of MDM4 protein levels [50,51].  
Importin   
  Within the RING finger, MDM4 possesses a stretch of 
basic aa that represents a putative nuclear localization signal 
[1]. Indeed, upon DNA damage MDM4 translocates in the 
nucleus, also independently of its shuttling protein MDM2 
[52]. GST-pull down experiments have shown interaction of 
MDM4 with the cytoplasmic receptors importin  [26]. Point 
mutation of MDM4 basic amino acid, K468, impairs MDM4 
binding to importin  and nuclear translocation after DNA 
damage suggesting a potential role for this association at 
least under some conditions.  
P14
Arf 
  The binding of MDM4 to p14
ARF is controversial since 
different groups have published opposing results with over-
expressed tagged proteins [53-55]. Definitely, it requires 
confirmation with the endogenous proteins. However, inter-
ference of MDM4 towards p14
ARF activity [55] as well as of 
p14
ARF towards MDM4 function [54] has been reported sug-
gesting the potential existence of a crosstalk between these 
two proteins. 
P21 
  The binding of MDM4 to the cyclin-dependent kinase 
inhibitor, p21 (CDKN1A), requires at least three regions, 
one comprising the BD, the second the central region (aa 
233-322), the third encompassing the RING finger domain 
(aa 423-490) [56]. Whether the three regions represent all 
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of the binding pocket remains to be ascertained. The MDM4 
function toward p21 promotes proteosomal turnover of p21.  
P300 
  The association between MDM4 and the co-activator 
p300 has been assessed only by in vitro experiments [57]. 
However, the ability of MDM4 to interfere with p300 activ-
ity has been reported. This interference results in decrease of 
p300-mediated acetylated p53 [58] and in the impairment of 
the interaction of p300 with the transcriptional factors 
Smad3 and 4 that in turn invalidates the activity of these last 
[57].  
pRB (Retinoblastoma Protein) 
  Coimmunoprecipitation experiments in tumor cell lines 
have shown the association between endogenous proteins 
MDM4 and pRB [59]. Although the MDM4 region respon-
sible for such binding has not been mapped, the C-terminus 
(aa 405-490) is not required. Further, the possibility that this 
association is mediated by other proteins cannot be ruled out. 
In the report of Kitagawa’s group, MDM4 counteracts 
MDM2-mediated degradation of pRB, thus positively regu-
lating its protein levels and transcriptional function [59].  
S2 
  Recently, MDM4 has been  shown to interact with the 
subunit S2 (Rpn1) of the 26S proteasome [56]. In this report, 
the BD and the C-terminus regions of MDM4 are both re-
quired for the association although the C-terminus loss 
slightly impairs the binding [56] (Di Conza et al., unpub-
lished data). This association is presumed to confer to 
MDM4 the ability to promote proteosomal degradation of 
the cyclin dependent inhibitor p21.  
SMAD 3 and 4 
  Similarly to E2F1, contradictory results have been pro-
vided about this association [57, 60]. However, an inhibitory 
function of MDM4 toward these two transcription factors 
has been reported in two independent reports. 
MDM4 Variants 
  Analysis of human tumors has evidenced aberrant ex-
pression of MDM4 in different human tumors characterized 
by wild type TRP53 supporting the hypothesis of an impor-
tant role of MDM4 in the control of p53 in human tumori-
genesis. The more frequent event observed in human tumors 
is the amplification of the gene [42]. In addition, the pres-
ence of shorter forms of MDM4 besides the full-length pro-
tein has emerged. The first observation derived from Jo-
chemsen’s group, which reported the presence by im-
munoblot (WB) analysis of at least 5 shorter MDM4 forms 
in a panel of 31 human tumor cell lines [61]. Only one of 
them, resolving at kDa 30,000, was detected in normal cells, 
melanocytes, suggesting the occurrence of the other forms 
specifically in tumor cells. Since then, 7 shorter forms of 
MDM4 have been characterized. All, but one, derived from 
alternative splicing (Fig. 2). These transcript variants are 
described in more details in the following paragraphs.  
MDM4-S 
  Mdm4-S was the first transcript variant identified in mur-
ine and in human cells [62]. Human MDM4-S is the product 
of an internal deletion of 68 base pairs, occurring at the level 
of exon 6. This deletion produces a shift of the reading frame 
after codon 114 and introduces a new translation stop codon 
following amino acid 140 (Fig. 2b). The result of this splic-
ing is a truncated protein that encodes for the first 114 aa of 
full-length (fl) MDM4 (the entire p53 binding domain) with 
the addition of C-terminal 26 aa residues (13 in the murine 
protein) [16]. In immunoblot, the MDM4-S size of 27kDa is 
higher than its predicted molecular mass of 15kDa, suggest-
ing the presence of posttranslational modifications as hy-
pothesized for fl-MDM4. In agreement with its structure, 
MDM4-S associates with p53. However, its affinity toward 
p53 is approximately 10 fold higher than that of fl-MDM4 
(analyzed by GST pull down) [62, 63]. As a consequence, 
MDM4-S is a more potent suppressor of p53 transcriptional 
activity. Analysis of nuclear and cytosolic fractions indicates 
that endogenous MDM4-S is localized in the nucleus [62, 
63]. Whether the nuclear localization of MDM4-S may be 
responsible, at least in part, for the enhanced inhibition of 
p53 has not been ascertained.  
  The MDM4-S-mediated impairment of p53 function has 
been hypothesized as the basis for its oncogenic potential 
[62]. In addition, the lack of other portions of fl-MDM4 pro-
tein should make MDM4-S insensitive to the regulatory 
modifications thus far reported, particularly those regarding 
the destabilization of protein levels. Although comparison of 
MDM4-S and fl-MDM4 protein stability has not been per-
formed, this property would make MDM4-S even more on-
cogenic that fl-MDM4. In agreement with the hypothesis of 
higher oncogenic properties of MDM4-S in comparison to fl-
MDM4,  analysis of tumor cell lines and samples has evi-
denced levels of MDM4-S transcript exceeding those of the 
fl-MDM4, with a certain frequency [62, 64, 65]. On the con-
trary, in normal tissues the ratio MDM4-S to fl-MDM4 never 
exceed 1.1 with majority of values <1 [64, 65]. Interestingly, 
in growing cells in comparison to serum starved cells 
MDM4-S transcript is increased, confirming its positive role 
in cell growth [62]. 
  Thus far, analysis of MDM4-S mRNA and/or protein has 
been evaluated in three different groups of tumor samples: in 
a group of 208 gliomas [66], a group of 66 primary soft tis-
sue sarcomas (STS) [64], and a group of 57 papillary thyroid 
tumors (PTC) [65]. MDM4-S is detectable in 78% of the STS 
samples and in 91% of PTC while the frequency of its over-
expression ranges from 19% to 35% in the two groups. In all 
three groups, the levels of MDM4-S do not correlate with 
increased levels of fl-MDM4 mRNA suggesting that the 
overexpression of MDM4-S is independent of MDM4 mRNA 
levels. 
  The analysis of association of MDM4-S overexpression 
with tumor properties has evidenced a significant correlation 
with an unfavorable prognosis of STS patients [64]. Intrigu-
ingly, in this report there is no association between MDM4-S 
overexpression and p53 status, suggesting that MDM4-S 
might exerts its function towards targets other than wt-p53. It 
would be interesting to investigate whether it exerts any 
positive regulation of mutant p53. In analogy to data re-
ported for STS, a significant association of MDM4-S over-
expression has been reported with high grade glioblastomas 
[66] supporting the hypothesis that MDM4-S, better than fl-
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MDM4-A and MDM4-G 
  MDM4-A and MDM4-G have been characterized in 
C33A cells [67]. Although the endogenous protein product 
of their transcripts has not been evidenced, the analysis of 
their activity has evidenced some potential interesting prop-
erties of MDM4 variants.  
  MDM4-A lacks most of the acidic region (deletion of aa 
225-274) (Fig. 2b). This loss results in a strong susceptibility 
of this variant to the MDM2 degradative activity, pointing to 
an important role of this domain in the stability of fl-MDM4. 
Although detailed studies are necessary to clarify the mecha-
nism that underlie MDM4-A destabilization, it has been pro-
posed that the acidic domain of MDM4 might mask the 
acidic domain of MDM2 and inhibit its degradative function 
especially toward p53, which depends also on the presence 
of this domain [67]. Thus, this MDM4 variant might possess 
oncogenic properties by functioning in complex with MDM2 
to enhance the degradative function of it. 
  The MDM4-G variant results from an in-frame deletion 
of aa 27-124, encompassing the p53-binding domain (Fig. 
2b). Interestingly this variant, which is unable to bind p53, 
still possesses inhibitory activity toward p53 although less 
pronounced than that of fl-MDM4. This inhibition has been 
attributed to the stabilization of MDM2 levels and conse-
quently of its oncogenic properties.  
  These data highlight the complexity of the function of 
MDM4 variants that might rely on the alteration of the activ-
ity of other oncogenic proteins, as MDM2 and/or MDM4, 
rather than on intrinsic tumor promoting properties.  
MDM4-211 
  MDM4-211 is a variant of human MDM4 identified in a 
thyroid tumor cell line [68]. This form derives from an aber-
rant splicing event between the canonical donor site in exon 
2 and a cryptic acceptor site in exon 11 of MDM4 fl-mRNA. 
The resulting protein contains the first 26 amino acids and 
the last 138 amino acids of fl-MDM4 (Fig. 2b). For this pro-
tein too, as for MDM4-S, the predicted molecular weight 
does not correspond to the molecular weight observed in 
SDS-PAGE suggesting the presence of covalent modifica-
tions. MDM4-211 does not bind p53 because of the almost 
complete loss of the p53 binding domain. Indeed, direct ac-
tivity of MDM4-211 toward the p53 oncosuppressor was not 
observed. On the contrary, MDM4-211 binds MDM2 
through the C-terminus and stabilizes its protein levels by 
increasing the protein half life. Particularly, MDM4-211 
seems to function as an inhibitor of MDM2 degradative 
function causing stabilization of p53 in addition to MDM2. 
Interestingly, the resulting p53 is transcriptionally inactive, 
raising the hypothesis that MDM4-211 may stabilize an inac-
tive complex, MDM2-p53, by binding to it. The oncogenic 
properties of MDM4-211 might therefore rely on both stabi-
lization of the oncoprotein MDM2 and inactivation of p53. 
In fact, colony assays have shown transforming potential 
ability of MDM4-211 both in a p53-null and wild type back-
ground supporting the hypothesis that the primary target of 
MDM4-211 is the oncogenic MDM2 [68].  
  In human tumors, MDM4-211 was found in 2 out of 16 
non–small-cell lung cancers [68]. In addition, MDM4-211 
was found with a frequency of 18% in a group of 83 papil-
lary thyroid carcinomas (PTC) [65]. No correlation with tu-
mor properties has been reported. In most of the tumors ex-
pressing MDM4-211, MDM2 showed enhanced protein lev-
els not associated to gene amplification, confirming the mo-
lecular model proposed. Importantly, MDM4-211 was never 
found in normal tissues, suggesting it derives from an aber-
rant event occurring only in tumor cells [65, 68]. In analogy 
to what happens for MDM4-S, the expression of MDM4-211 
does not correlate with the levels of fl-MDM4 transcript sug-
gesting the independency of this splicing event from the 
abundance of fl-MDM4 transcript. 
  Besides the effect toward MDM2, MDM4-211 maintains 
the interaction with fl-MDM4. Thus, some of its activities 
could also rely on the deregulation and/or squelching of 
other factors from fl-MDM4. Particularly, MDM4-211 main-
tains the 14-3-3 binding site and might therefore decrease the 
interaction of MDM4 with these proteins and consequently 
impair the MDM4 degradation mediated by this association, 
thus enhancing the oncogenic potential of fl-MDM4.  
MDM4-XALT1 and –XALT2 
  In 2006, along the analysis of MDM2 alternative tran-
scripts induced by UV irradiation in some human tumor cell 
lines, Lozano’s group found out two alternative transcripts of 
MDM4, called XALT1 and XALT2 [69]. XALT1 derives from 
a splicing event between exon 5 and exon 10 of MDM4 fl-
mRNA while XALT2 derives from a splicing between exon 3 
and exon 10 (Fig. 2b). The predicted protein of XALT1 tran-
script possesses only the p53 binding domain. As a conse-
quence, it is presumed to bind p53 and to suppress its tran-
scriptional activity as occurs for the MDMX-S form. Con-
versely, the predicted protein of XALT2 transcript lacks the 
p53 binding domain and retains the COOH-terminal RING 
finger domain. Thus, this variant may bind fl-MDM4 and/or 
MDM2 and regulate their function. Interestingly, a transcript 
analogous to XALT2 has been described for MDM2 under 
the same conditions.  
  These forms have been evidenced in different tumor cell 
lines. Their presence has been supposed to be a further layer 
of regulation of the p53-MDM2-MDM4 network in response 
to DNA damage. However, their presence after high doses of 
UV irradiation, which probably induce an apoptotic re-
sponse, might also represent a survival response of tumor 
cells. Indeed, XALT1 might limit p53 activity while XALT2 
might stabilize MDM2 protein levels and its antiapoptotic 
function [70]. The expression of these variants in non tumor 
cells might help to discriminate their function [69].  
Role of MDM4 Variants in Human Tumorigenesis 
  The two members of the MDM family, MDM2 and 
MDM4 are characterized by the presence of a large number 
of splicing variants. For MDM2, 40 splice variants have 
been described [71] while six for the younger MDM4 have 
been identified. It has to be pointed out that for majority of 
these variants it is presently unknown whether they are trans-
lated into protein.  
  Most of them have been recognized only in tumor sam-
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rearrangement of fl-mRNA splicing have not been provided. 
Some conserved sequence blocks for the splicing factors 
SC35 and SRp40 have been recognized in MDM4 and 
MDM2 but their function has not been investigated [69]. 
Similarly, in MDM2 some regions have been identified hav-
ing high sequence homology and repeated occurrence (at 
least 4 times) [71]. However, the same regions are not rec-
ognizable in MDM4, thus not supporting a role for them at 
least in MDM4 splicing.  
  The recovery of some of the MDM4 variants, as well as 
of MDM2, in tumor cells and the analysis of their activity 
suggest that they may possess tumorigenic activity. For 
MDM2 some studies have indeed confirmed such activity in 
in vivo models [72,73]. For MDM4 similar models have not 
yet been developed.  
  The discrimination of the oncogenic activities of these 
variants represents a difficult task. Indeed, their ability to 
bind and modify the function of their fl-counterparts, MDM2 
and MDM4, intertwine their direct activity towards targets as 
p53 and affects the functional outcome of their expression. 
Thus, their activity may reside not only in their intrinsic 
properties but also in their ability to squelch out binding 
partners from MDM4/MDM2 and/or sequester the fl-
proteins. In addition, the ratio of expression levels of these 
variants to those of fl-MDM proteins represents an additional 
variable in the study of their function. Indeed, analysis of 
tumor samples has shown the absence of any correlation 
between the levels of MDM4-S or MDM4-211 and fl-
MDM4 transcript suggesting independency of their expres-
sion.  
  Interestingly, the MDM4 variants may be roughly distin-
guished in two groups: one preserving the p53 binding do-
main and the other preserving the COOH-terminus where 
MDM2 binding resides (Fig. 2a and b). With the exception 
of MDM4-A, the presence of one of these two portions ap-
pears to exclude the other. Although, the number of MDM4 
variants identified thus far is too low to draw out any certain 
prediction, this observation might suggest that the central 
part of MDM4 exerts a regulatory function counterselected 
by transformation process. In agreement with this hypothe-
sis, most of the MDM4 modifications thus far identified re-




















Fig. (2). (a) Scheme of MDM4 mRNA organization in exons (according to the GeneBank NM 002393) paralleled to the structure of the 
MDM4 protein regions. (b) Scheme of mRNA of MDM4 variants.  48    Current Genomics, 2009, Vol. 10, No. 1  Mancini et al. 
  Analysis of the association of MDM4 variant expression 
with tumor properties has evidenced some significant corre-
lations. These data may suggest a potential role of these 
MDM4 forms as molecular predictors of cancer features. 
  Finally, an important issue raised by the identification of 
MDM4 and MDM2 variants is the need to develop accurate 
detection systems able to distinguish the fl-MDM molecules 
from their variants in the tumor samples both at the levels of 
mRNA as well as of protein. This requires the development 
of specific primers for RT-PCR and most importantly of 
specific antibodies in immunohistochemistry. This aspect 
seems of particular relevance in view of the lack of a correla-
tion between the presence of these variants and the levels of 
the full-length transcript. 
CONCLUSIONS 
  The discovery of MDM4 in 1996 has added a further 
layer of complexity to the regulation of p53 by MDM2. 
Nowadays, the different molecular activities exerted by the 
two MDM proteins toward p53 have originated at least three 
models of in vivo function, indicating the difficulties to join 
in an unmatched view all experimental data thus far pro-
vided. The uncovering of different variants of both MDM2 
and MDM4 increases even more the complexity of this pic-
ture that requires additional investigation of MDM function, 
especially along the tumorigenic process. It represents an 
interesting challenge in the investigation of tumor biology 
and of particular relevance in view of the proposal of tar-
geted therapies toward specific molecules, such as those 
based on the release of p53 oncosuppressive function from 
MDM constraint.  
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